Business Context and Reporting Period
Company: Ekso Bionics Holdings, Inc. (Ticker: EKSO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: The Company designs, develops, and markets wearable powered and non-powered exoskeleton products for neurorehabilitation (EksoHealth segment) and industrial applications (EksoWorks segment). The Company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $4,950 | $8,706 |
| Gross Profit | $2,637 | $4,588 |
| Gross Margin | 53% | 53% |
| Net Loss | $(2,416) | $(5,845) |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.33) |
| Cash and Restricted Cash | $5,885 | $5,885 (Balance Sheet) |
| Unrestricted Cash | ~$3,885 | ~$3,885 |
| Total Debt (Notes Payable) | $5,602 | $5,602 |
| Working Capital | $10,938 | $10,938 |
Note: Total Debt includes $1,250 current and $4,352 non-current notes payable. Unrestricted cash is calculated after deducting $2,000 restricted cash required by the Pacific Western Bank term loan covenant.
Material Changes vs. Prior Period
- Revenue: For the three months ended June 30, 2024, revenue increased 5% ($247k) compared to the same period in 2023, driven by higher average selling prices for the EksoNR and increased EVO sales. For the six-month period, revenue decreased slightly by 1% ($119k) due to lower EksoNR device volume, partially offset by Indego and EVO growth.
- Gross Margin: Improved to 53% for both the three and six-month periods in 2024, up from 48% in the comparable 2023 periods. This was driven by higher average selling prices and reduced service and supply chain costs.
- Operating Expenses: Total operating expenses decreased 24% ($1.6M) for the quarter and 22% ($2.8M) for the six months compared to 2023. Reductions were seen across Sales & Marketing, R&D, and G&A, primarily due to lower headcount, consultant costs, and the absence of acquisition integration costs in the current period.
- Net Loss: Net loss narrowed significantly, decreasing 43% for the quarter and 32% for the six months compared to the prior year periods.
- Other Income/Expense: The six-month period included a $426k gain on the revaluation of warrant liabilities and a $440k unrealized loss on foreign exchange.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for 12 months from the issuance date. The Company has an accumulated deficit of $244.99M and expects to continue incurring operating losses. Additional financing is required to fund operations.
- Financing Activities: In January 2024, the Company completed a registered direct offering raising ~$3.9M. In July 2024, the Company filed a Form S-1 for a potential offering of common stock and pre-funded warrants. An "At The Market" (ATM) program remains active with $4.1M available.
- Reimbursement: In April 2024, CMS approved a final payment level of $91,031.93 for the Ekso Indego Personal device, effective April 1, 2024. The Company expects this to drive demand in the Personal Health business line.
- Regulatory Risks: The Company is in the process of obtaining CE Certificates of Conformity under the EU MDR for its Indego products. Failure to comply by the December 31, 2028 deadline would prevent sales in the EU.
- Debt Covenants: The Company must maintain cash on hand equivalent to the outstanding principal balance of its Pacific Western Bank term loan ($2.0M), which restricts liquidity.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of the proposed Form S-1 offering given the "substantial doubt" going concern disclosure and current unrestricted cash of ~$3.9M.
- CMS Reimbursement Impact: Monitor actual sales volume of the Ekso Indego Personal device following the April 2024 CMS approval to assess if it materializes into significant revenue growth.
- Debt Compliance: Confirm continued compliance with the Pacific Western Bank liquidity covenant requiring $2.0M in restricted cash.
- EU Regulatory Status: Track progress on obtaining CE Certificates under the EU MDR to ensure access to European markets remains viable.
- Customer Concentration: Note that two customers accounted for 15% and 10% of accounts receivable as of June 30, 2024, and two customers accounted for 11% and 10% of revenue in Q2 2024.